Investors

Investors 2017-08-18T12:57:17+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

ASX Announcement – Results of AGM

The results from the Dimerix 2017 AGM are available here.

ASX Announcement – AGM Presentation

The Dimerix AGM is today, 19 October 2017. The presentation that CEO Kathy Harrison will use is available here. NOTE: This presentation replaces a previous version that erroneously did not include a financial disclosure slide. [...]

ASX Announcement – Dimerix appoints Medical Advisory Board

We are very pleased to announce the appointment of a Medical Advisory Board (MAB) to help guide the Company’s DMX-200 clinical program. The Medical Advisory Board will provide clinical and strategic input into the Company’s [...]

Dimerix receives $545k Research and Development Tax Refund

Dimerix (ASX:DXB) is pleased to announce the receipt of a Research and Development (R&D) Tax Incentive refund of $545,771 for the 2016/2017 financial year. The refund relates to eligible expenditure on the company’s lead program, [...]

Read More

Media Coverage

Dimerix in the news following positive Phase 2a trial results in Chronic Kidney Disease

As you may know, Dimerix was pleased to release positive results for our DMX-200 Phase 2a trial in Chronic Kidney Disease (CKD) on 12 July 2017. You can see that announcement here. Following the data [...]

Video: NDF Research interview on Phase 2a results

In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with [...]

NDF Research: An update report on Dimerix

View the update analyst report on their website.

The Australian: “Trial results ‘exciting’ for biotech Dimerix”

Dimerix CEO Kathy Harrison interviewed by The Australian Read the article on their website.

Read More

Stock Quote

View stock price: ASX Stock Price

Email Alert

subscribe to news updates